UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease.

Autor: Buka RJ; Institute of Cardiovascular Sciences University of Birmingham Birmingham UK.; HaemSTAR Birmingham UK., Roy N; Department of Haematology Oxford University Hospitals NHS Foundation Trust Oxford UK., Nicolson PL; Institute of Cardiovascular Sciences University of Birmingham Birmingham UK.; HaemSTAR Birmingham UK.
Jazyk: angličtina
Zdroj: EJHaem [EJHaem] 2022 Dec 25; Vol. 4 (1), pp. 13-17. Date of Electronic Publication: 2022 Dec 25 (Print Publication: 2023).
DOI: 10.1002/jha2.623
Abstrakt: Crizanlizumab was recommended for use in patients with sickle cell disease in the UK in October 2021 and received widespread media coverage. Accuracy of reporting is paramount in building trust with this group of patients who are often wary of the medical profession. We carried out an analysis of internet-based news articles and applied a validated scoring system to assess quality. 21 articles from 19 media organisations were identified. 71% of articles stated unproven benefits of the drug and only 14% were of satisfactory quality. The former was largely due to quoting of two NHS England press releases. Overstating of drug efficacy may be detrimental to the need to address healthcare inequalities.
Competing Interests: RB has received a research grant from AstraZeneca. NR has no conflicts of interest to disclose. PN has received research grants from Novartis, Principia, Rigel, and Sanofi and speaker fees from Bayer, Sobi, Takeda and Grifols.
(© 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: